Cerus Corporation

6.59+0.1800+2.81%Vol 539.08K1Y Perf 10.95%
Sep 23rd, 2021 13:02 DELAYED
BID6.59 ASK6.60
Open6.51 Previous Close6.41
Pre-Market6.52 After-Market-
 0.11 1.72%  - -
Target Price
8.90 
Analyst Rating
Strong Buy 1.00
Potential %
36.09 
Finscreener Ranking
★★+     48.59
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     42.04
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★+     41.45
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
45.71 
Earnings Rating
Sell
Market Cap1.13B 
Earnings Date
4th Nov 2021
Alpha-0.00 Standard Deviation0.16
Beta1.22 

Today's Price Range

6.426.60

52W Range

4.678.87

5 Year PE Ratio Range

-8.40-7.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
2.56%
1 Month
5.43%
3 Months
12.46%
6 Months
5.08%
1 Year
10.95%
3 Years
-12.91%
5 Years
2.89%
10 Years
209.66%

TickerPriceChg.Chg.%
CERS6.590.18002.81
AAPL146.600.75000.51
GOOG2 836.3217.55000.62
MSFT299.611.03000.34
XOM57.051.84003.33
WFC48.050.97002.06
JNJ165.541.61000.98
FB345.422.21000.64
GE103.925.38005.46
JPM161.225.31003.41
Financial StrengthValueIndustryS&P 500US Markets
2.20
2.80
0.46
0.97
-13.60
Leverage Ratio 2.30
ProfitabilityValueIndustryS&P 500US Markets
53.60
-43.70
-41.20
-92.80
-46.97
RevenueValueIndustryS&P 500US Markets
130.11M
0.76
19.19
28.24
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.10-0.0910.00
Q01 2021-0.09-0.10-11.11
Q04 2020-0.08-0.09-12.50
Q03 2020-0.12-0.0833.33
Q02 2020-0.10-0.0910.00
Q01 2020-0.10-0.100.00
Q04 2019-0.11-0.12-9.09
Q03 2019-0.11-0.13-18.18
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.10-11.11Negative
12/2021 QR-0.09-12.50Negative
12/2021 FY-0.370.00-
12/2022 FY-0.32-3.23Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.10
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume539.08K
Shares Outstanding171.63M
Shares Float137.89M
Trades Count3.70K
Dollar Volume24.89M
Avg. Volume1.80M
Avg. Weekly Volume1.26M
Avg. Monthly Volume932.45K
Avg. Quarterly Volume1.38M

Cerus Corporation (NASDAQ: CERS) stock closed at 6.41 per share at the end of the most recent trading day (a 0.63% change compared to the prior day closing price) with a volume of 757.78K shares and market capitalization of 1.13B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 270 people. Cerus Corporation CEO is William M. Greenman.

The one-year performance of Cerus Corporation stock is 10.95%, while year-to-date (YTD) performance is -7.37%. CERS stock has a five-year performance of 2.89%. Its 52-week range is between 4.67 and 8.87, which gives CERS stock a 52-week price range ratio of 45.71%

Cerus Corporation currently has a PE ratio of -18.50, a price-to-book (PB) ratio of 13.57, a price-to-sale (PS) ratio of 8.40, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -27.22%, a ROC of -34.15% and a ROE of -59.82%. The company’s profit margin is -46.97%, its EBITDA margin is -41.20%, and its revenue ttm is $130.11 Million , which makes it $0.76 revenue per share.

Of the last four earnings reports from Cerus Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.10 for the next earnings report. Cerus Corporation’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Cerus Corporation is Strong Buy (1), with a target price of $8.9, which is +36.09% compared to the current price. The earnings rating for Cerus Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cerus Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cerus Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 21.84, ATR14 : 0.22, CCI20 : 34.65, Chaikin Money Flow : 0.00, MACD : 0.12, Money Flow Index : 42.51, ROC : -1.23, RSI : 56.99, STOCH (14,3) : 59.09, STOCH RSI : 0.45, UO : 50.58, Williams %R : -40.91), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cerus Corporation in the last 12-months were: Carol M. Moore (Option Excercise at a value of $0), Carol M. Moore (Sold 29 331 shares of value $187 064 ), Chrystal Menard (Option Excercise at a value of $1 141 904), Chrystal Menard (Sold 290 146 shares of value $2 273 584 ), Daniel N. Swisher (Option Excercise at a value of $109 328), Daniel N. Swisher (Sold 37 877 shares of value $249 518 ), Eric H. Bjerkholt (Option Excercise at a value of $0), Gail Gaumer Schulze (Option Excercise at a value of $37 200), Gail Gaumer Schulze (Sold 62 393 shares of value $456 817 ), Jami Dover Nachtsheim (Option Excercise at a value of $0), Kevin D. Green (Option Excercise at a value of $0), Kevin D. Green (Sold 62 259 shares of value $367 926 ), Laurence M. Corash (Option Excercise at a value of $92 232), Laurence M. Corash (Sold 23 775 shares of value $151 630 ), Richard J. Benjamin (Option Excercise at a value of $0), Richard J. Benjamin (Sold 49 331 shares of value $313 844 ), Timothy B. Anderson (Option Excercise at a value of $162 000), Timothy B. Anderson (Sold 39 336 shares of value $326 856 ), Timothy L. Moore (Option Excercise at a value of $0), Vivek K. Jayaraman (Option Excercise at a value of $406 031), Vivek K. Jayaraman (Sold 181 044 shares of value $1 388 085 ), William M. Greenman (Option Excercise at a value of $1 693 000), William M. Greenman (Sold 156 407 shares of value $997 517 ), Witney Frank (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
4 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cerus Corporation

Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: blood safety and generates revenue from the same.

CEO: William M. Greenman

Telephone: +1 925 288-6000

Address: 1220 Concord Avenue, Concord 94520, CA, US

Number of employees: 270

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

62%38%

News

Stocktwits